CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Cancer of the Breast|Breast Cancer|Advanced Breast Cancer|Metastatic Breast Cancer|Male Breast Cancer|Triple Negative Breast Cancer|ER+ Breast Cancer
Interventions: DRUG: Seviteronel
Sponsor: Innocrin Pharmaceutical